Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
ESSA Pharma Inc
NASDAQ EPIX
Data sourced from
and
and
ESSA Pharma Inc Working Capital for the quarter ending March 31, 2024: USD 133.12 M
ESSA Pharma Inc Working Capital is USD 133.12 M for the quarter ending March 31, 2024, a -14.86% change year over year. Working Capital is the difference between a company's current assets and current liabilities, representing its short-term liquidity position.
-
ESSA Pharma Inc Working Capital for the quarter ending March 31, 2023 was USD 156.36 M, a -12.33% change year over year.
-
ESSA Pharma Inc Working Capital for the quarter ending March 31, 2022 was USD 178.35 M, a -13.51% change year over year.
-
ESSA Pharma Inc Working Capital for the quarter ending March 31, 2021 was USD 206.20 M, a 418.80% change year over year.
-
ESSA Pharma Inc Working Capital for the quarter ending March 31, 2020 was USD 39.75 M, a 639.91% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: EPIX
| CEO | Dr. David Ross Parkinson M.D. |
| IPO Date | July 9, 2015 |
| Location | Canada |
| Headquarters | 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 |
| Employees | 50 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email